Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

globenewswire.com
TLRY The article mentions Tilray Brands in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Tilray's performance or pipeline progress are provided, hence the neutral sentiment. TAK Takeda Pharmaceutical Company is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Takeda. TNDM The article mentions Tandem Diabetes Care in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Tandem's performance or pipeline progress are provided, hence the neutral sentiment. NVS Novartis is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Novartis. BMY Bristol Myers Squibb is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for BMS. PFE Pfizer is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Pfizer. INCY Incyte Corporation is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Incyte. JNJ Johnson & Johnson is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Johnson & Johnson. AZN AstraZeneca is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for AstraZeneca. MRK Merck & Co. is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Merck. ABBV AbbVie Inc. is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for AbbVie. CRSP CRISPR Therapeutics is mentioned as a key company in the chronic myeloid leukemia (CML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for CRISPR Therapeutics. SCLX The article mentions Scilex Holding Company in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Scilex's performance or pipeline progress are provided, hence the neutral sentiment. RIGL Rigel Pharmaceuticals is mentioned as a key company in the acute myeloid leukemia (AML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Rigel. JAZZ Jazz Pharmaceuticals is mentioned as a key company in the acute myeloid leukemia (AML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Jazz Pharmaceuticals. GILD The article mentions Gilead Sciences in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Gilead's performance or pipeline progress are provided, hence the neutral sentiment. REGN The article mentions Regeneron Pharmaceuticals in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Regeneron's performance or pipeline progress are provided, hence the neutral sentiment. AMGN The article mentions Amgen Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Amgen's performance or pipeline progress are provided, hence the neutral sentiment. BIIB The article mentions Biogen Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Biogen's performance or pipeline progress are provided, hence the neutral sentiment. PTGX The article mentions Protagonist Therapeutics in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Protagonist's performance or pipeline progress are provided, hence the neutral sentiment. EXAS The article mentions Exact Sciences Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Exact Sciences' performance or pipeline progress are provided, hence the neutral sentiment. SNOW The article mentions Snowflake Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Snowflake's performance or pipeline progress are provided, hence the neutral sentiment. SRPT The article mentions Sarepta Therapeutics in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Sarepta's performance or pipeline progress are provided, hence the neutral sentiment. VRTX The article mentions Vertex Pharmaceuticals in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Vertex's performance or pipeline progress are provided, hence the neutral sentiment. BNTX The article mentions BioNTech SE in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about BioNTech's performance or pipeline progress are provided, hence the neutral sentiment. ALKS The article mentions Alkermes plc in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Alkermes' performance or pipeline progress are provided, hence the neutral sentiment. RGEN The article mentions Repligen Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Repligen's performance or pipeline progress are provided, hence the neutral sentiment. IMUX The article mentions Imunon, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Imunon's performance or pipeline progress are provided, hence the neutral sentiment. ADPT The article mentions Adaptive Biotechnologies Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Adaptive Biotechnologies' performance or pipeline progress are provided, hence the neutral sentiment. ATRC The article mentions Atreca, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Atreca's performance or pipeline progress are provided, hence the neutral sentiment. CRNX The article mentions Corvus Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Corvus Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. CYTK The article mentions Cytokinetics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Cytokinetics' performance or pipeline progress are provided, hence the neutral sentiment. DTIL The article mentions Detilof Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Detilof's performance or pipeline progress are provided, hence the neutral sentiment. EXEL The article mentions Exelixis, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Exelixis' performance or pipeline progress are provided, hence the neutral sentiment. FGEN The article mentions FibroGen, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about FibroGen's performance or pipeline progress are provided, hence the neutral sentiment. GALT The article mentions Galectin Therapeutics Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Galectin Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. GNTX The article mentions Genentech, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Genentech's performance or pipeline progress are provided, hence the neutral sentiment. GRFS The article mentions Greenwich Life Sciences, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Greenwich Life Sciences' performance or pipeline progress are provided, hence the neutral sentiment. GSK The article mentions GSK plc in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about GSK's performance or pipeline progress are provided, hence the neutral sentiment. HRMY The article mentions Harmony Biosciences Holdings, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Harmony Biosciences' performance or pipeline progress are provided, hence the neutral sentiment. IDXX The article mentions IDEXX Laboratories, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about IDEXX Laboratories' performance or pipeline progress are provided, hence the neutral sentiment. ILMN The article mentions Illumina, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Illumina's performance or pipeline progress are provided, hence the neutral sentiment. INSM The article mentions Insmed Incorporated in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Insmed's performance or pipeline progress are provided, hence the neutral sentiment. IONS The article mentions Ionis Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Ionis Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. IRWD The article mentions Ironwood Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Ironwood Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. KODK The article mentions Eastman Kodak Company in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Eastman Kodak's performance or pipeline progress are provided, hence the neutral sentiment. LAKE The article mentions Lake Shore Bancorp, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Lake Shore Bancorp's performance or pipeline progress are provided, hence the neutral sentiment. LULU The article mentions Lululemon Athletica Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Lululemon's performance or pipeline progress are provided, hence the neutral sentiment. LYFT The article mentions Lyft, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Lyft's performance or pipeline progress are provided, hence the neutral sentiment. MAR The article mentions Marriott International, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Marriott's performance or pipeline progress are provided, hence the neutral sentiment. MDLZ The article mentions Mondelez International, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Mondelez's performance or pipeline progress are provided, hence the neutral sentiment. MELI The article mentions MercadoLibre, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about MercadoLibre's performance or pipeline progress are provided, hence the neutral sentiment. MIRM The article mentions Mirum Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Mirum Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. MNKD The article mentions MannKind Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about MannKind's performance or pipeline progress are provided, hence the neutral sentiment. MRNA The article mentions Moderna, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Moderna's performance or pipeline progress are provided, hence the neutral sentiment. MTCH The article mentions Match Group, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Match Group's performance or pipeline progress are provided, hence the neutral sentiment. NBIX The article mentions Neurocrine Biosciences, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Neurocrine Biosciences' performance or pipeline progress are provided, hence the neutral sentiment. NCLH The article mentions Norwegian Cruise Line Holdings Ltd. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Norwegian Cruise Line's performance or pipeline progress are provided, hence the neutral sentiment. NEM The article mentions Newmont Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Newmont's performance or pipeline progress are provided, hence the neutral sentiment. NTRA The article mentions Natera, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Natera's performance or pipeline progress are provided, hence the neutral sentiment. NVCR The article mentions Novocure Limited in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Novocure's performance or pipeline progress are provided, hence the neutral sentiment. ODFL The article mentions Old Dominion Freight Line, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Old Dominion Freight Line's performance or pipeline progress are provided, hence the neutral sentiment. OMER The article mentions Omeros Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Omeros Corporation's performance or pipeline progress are provided, hence the neutral sentiment. ORGO The article mentions Organon & Co. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Organon & Co.'s performance or pipeline progress are provided, hence the neutral sentiment. OTEX The article mentions Open Text Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Open Text's performance or pipeline progress are provided, hence the neutral sentiment. PACB The article mentions Pacific Biosciences of California, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Pacific Biosciences' performance or pipeline progress are provided, hence the neutral sentiment. PBYI The article mentions Puma Biotechnology, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Puma Biotechnology's performance or pipeline progress are provided, hence the neutral sentiment. PCAR The article mentions PACCAR Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about PACCAR's performance or pipeline progress are provided, hence the neutral sentiment. PEGA The article mentions Pegasystems Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Pegasystems' performance or pipeline progress are provided, hence the neutral sentiment. PERI The article mentions Perion Network Ltd. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Perion Network's performance or pipeline progress are provided, hence the neutral sentiment. PETS The article mentions PetMed Express, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about PetMed Express's performance or pipeline progress are provided, hence the neutral sentiment. PLRX The article mentions Plexxikon, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Plexxikon's performance or pipeline progress are provided, hence the neutral sentiment. PMVP The article mentions PMV Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about PMV Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. PPC The article mentions Pilgrim's Pride Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Pilgrim's Pride Corporation's performance or pipeline progress are provided, hence the neutral sentiment. PRGS The article mentions Progress Software Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Progress Software's performance or pipeline progress are provided, hence the neutral sentiment. PRTA The article mentions Portola Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Portola Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. PSNL The article mentions Personalis, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Personalis' performance or pipeline progress are provided, hence the neutral sentiment. PTN The article mentions Pernix Therapeutics Holdings, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Pernix Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. PZZA The article mentions Papa John's International, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Papa John's performance or pipeline progress are provided, hence the neutral sentiment. QGEN The article mentions Qiagen N.V. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Qiagen's performance or pipeline progress are provided, hence the neutral sentiment. QTRX The article mentions Quanterix Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Quanterix's performance or pipeline progress are provided, hence the neutral sentiment. RARE The article mentions Ultragenyx Pharmaceutical Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Ultragenyx Pharmaceutical's performance or pipeline progress are provided, hence the neutral sentiment. RCEL The article mentions Cellectar Biosciences, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Cellectar Biosciences' performance or pipeline progress are provided, hence the neutral sentiment. RDHL The article mentions Redhill Biopharma Ltd. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Redhill Biopharma's performance or pipeline progress are provided, hence the neutral sentiment. RLAY The article mentions Relay Therapeutics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Relay Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. RLGT The article mentions Radiant Logistics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Radiant Logistics' performance or pipeline progress are provided, hence the neutral sentiment. RMD The article mentions ResMed Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about ResMed's performance or pipeline progress are provided, hence the neutral sentiment. ROST The article mentions Ross Stores, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Ross Stores' performance or pipeline progress are provided, hence the neutral sentiment. RRX The article mentions Rattler, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Rattler's performance or pipeline progress are provided, hence the neutral sentiment. RYAAY The article mentions Ryanair Holdings plc in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Ryanair Holdings' performance or pipeline progress are provided, hence the neutral sentiment. RYTM The article mentions Rhythm Pharmaceuticals, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Rhythm Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. SAN The article mentions Banco Santander, S.A. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Banco Santander's performance or pipeline progress are provided, hence the neutral sentiment. SBAC The article mentions SBA Communications Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about SBA Communications' performance or pipeline progress are provided, hence the neutral sentiment. SBRA The article mentions Sabra Health Care REIT, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Sabra Health Care REIT's performance or pipeline progress are provided, hence the neutral sentiment. SEIC The article mentions SEI Investments Company in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about SEI Investments' performance or pipeline progress are provided, hence the neutral sentiment. SIGA The article mentions SIGA Technologies, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about SIGA Technologies' performance or pipeline progress are provided, hence the neutral sentiment. SIRI The article mentions Sirius XM Holdings Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Sirius XM's performance or pipeline progress are provided, hence the neutral sentiment. SITE The article mentions Site Centers Corp. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Site Centers' performance or pipeline progress are provided, hence the neutral sentiment. SLAB The article mentions Silicon Laboratories Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Silicon Laboratories' performance or pipeline progress are provided, hence the neutral sentiment. SLGN The article mentions Silgan Holdings Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Silgan Holdings' performance or pipeline progress are provided, hence the neutral sentiment. SMCI The article mentions Super Micro Computer, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Super Micro Computer's performance or pipeline progress are provided, hence the neutral sentiment. SMMT The article mentions Summit Therapeutics plc in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Summit Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. SNPS The article mentions Synopsys, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Synopsys' performance or pipeline progress are provided, hence the neutral sentiment. SNY Sanofi is mentioned as a key company in the acute myeloid leukemia (AML) market and pipeline. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Sanofi. SOFI The article mentions SoFi Technologies, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about SoFi Technologies' performance or pipeline progress are provided, hence the neutral sentiment. SONO The article mentions Sonos, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Sonos' performance or pipeline progress are provided, hence the neutral sentiment. SPCE The article mentions Virgin Galactic Holdings, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Virgin Galactic's performance or pipeline progress are provided, hence the neutral sentiment. SSYS The article mentions Stratasys Ltd. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Stratasys' performance or pipeline progress are provided, hence the neutral sentiment. STNG The article mentions Stingray Group Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Stingray Group's performance or pipeline progress are provided, hence the neutral sentiment. STRA The article mentions Strayer Education, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Strayer Education's performance or pipeline progress are provided, hence the neutral sentiment. STRL The article mentions Sterling Construction Company, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Sterling Construction Company's performance or pipeline progress are provided, hence the neutral sentiment. STX The article mentions Seagate Technology Holdings plc in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Seagate Technology's performance or pipeline progress are provided, hence the neutral sentiment. SWKS The article mentions Skyworks Solutions, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Skyworks Solutions' performance or pipeline progress are provided, hence the neutral sentiment. SYK The article mentions Stryker Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Stryker's performance or pipeline progress are provided, hence the neutral sentiment. SYNA The article mentions Synaptics Incorporated in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Synaptics' performance or pipeline progress are provided, hence the neutral sentiment. TCOM The article mentions Trip.com Group Limited in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Trip.com Group's performance or pipeline progress are provided, hence the neutral sentiment. TDOC The article mentions Teladoc Health, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Teladoc Health's performance or pipeline progress are provided, hence the neutral sentiment. TECK The article mentions Teck Resources Limited in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Teck Resources' performance or pipeline progress are provided, hence the neutral sentiment. TEVA Teva Pharmaceutical Industries Ltd. is mentioned as a key company in the chronic myeloid leukemia (CML) market. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Teva. TFX The article mentions Tactile Systems Technology, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Tactile Systems Technology's performance or pipeline progress are provided, hence the neutral sentiment. TGTX The article mentions TG Therapeutics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about TG Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. TIGR The article mentions Tiger Woods Design in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Tiger Woods Design's performance or pipeline progress are provided, hence the neutral sentiment. TRMB The article mentions Trimble Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Trimble's performance or pipeline progress are provided, hence the neutral sentiment. TRVG The article mentions Trade Group in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Trade Group's performance or pipeline progress are provided, hence the neutral sentiment. TTWO The article mentions Take-Two Interactive Software, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Take-Two Interactive Software's performance or pipeline progress are provided, hence the neutral sentiment. TUSK The article mentions Mammoth Energy Services, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Mammoth Energy Services' performance or pipeline progress are provided, hence the neutral sentiment. TXRH The article mentions Texas Roadhouse, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Texas Roadhouse's performance or pipeline progress are provided, hence the neutral sentiment. ULTA The article mentions Ulta Beauty, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Ulta Beauty's performance or pipeline progress are provided, hence the neutral sentiment. UMC The article mentions United Microelectronics Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about United Microelectronics' performance or pipeline progress are provided, hence the neutral sentiment. UNFI The article mentions United Natural Foods, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about United Natural Foods' performance or pipeline progress are provided, hence the neutral sentiment. UNH The article mentions UnitedHealth Group Incorporated in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about UnitedHealth Group's performance or pipeline progress are provided, hence the neutral sentiment. URBN The article mentions Urban Outfitters, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Urban Outfitters' performance or pipeline progress are provided, hence the neutral sentiment. UTHR The article mentions United Therapeutics Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about United Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. VEEV The article mentions Veeva Systems Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Veeva Systems' performance or pipeline progress are provided, hence the neutral sentiment. VELO The article mentions Velo3D, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Velo3D's performance or pipeline progress are provided, hence the neutral sentiment. VERU The article mentions Veru Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Veru's performance or pipeline progress are provided, hence the neutral sentiment. VIVO The article mentions Viela Bio, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Viela Bio's performance or pipeline progress are provided, hence the neutral sentiment. VKTX The article mentions Viking Therapeutics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Viking Therapeutics' performance or pipeline progress are provided, hence the neutral sentiment. VLRS The article mentions VLSI Technology LLC in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about VLSI Technology's performance or pipeline progress are provided, hence the neutral sentiment. VNDA The article mentions Vanda Pharmaceuticals Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Vanda Pharmaceuticals' performance or pipeline progress are provided, hence the neutral sentiment. VRSK The article mentions Verisk Analytics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Verisk Analytics' performance or pipeline progress are provided, hence the neutral sentiment. VSAT The article mentions Viasat Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Viasat's performance or pipeline progress are provided, hence the neutral sentiment. VTGN Viatris Inc. is mentioned as a key company in the chronic myeloid leukemia (CML) market. The article lists it among companies with active involvement, but provides no specific performance data or outlook for Viatris. WDC The article mentions Western Digital Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Western Digital's performance or pipeline progress are provided, hence the neutral sentiment. WEC The article mentions WEC Energy Group, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about WEC Energy Group's performance or pipeline progress are provided, hence the neutral sentiment. WERN The article mentions Werner Enterprises, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Werner Enterprises' performance or pipeline progress are provided, hence the neutral sentiment. WGO The article mentions Winnebago Industries, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Winnebago Industries' performance or pipeline progress are provided, hence the neutral sentiment. WIX The article mentions Wix.com Ltd. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Wix.com's performance or pipeline progress are provided, hence the neutral sentiment. WMB The article mentions The Williams Companies, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about The Williams Companies' performance or pipeline progress are provided, hence the neutral sentiment. WST The article mentions West Pharmaceutical Services, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about West Pharmaceutical Services' performance or pipeline progress are provided, hence the neutral sentiment. WTW The article mentions Willis Towers Watson Public Limited Company in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Willis Towers Watson's performance or pipeline progress are provided, hence the neutral sentiment. WYNN The article mentions Wynn Resorts, Limited in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Wynn Resorts' performance or pipeline progress are provided, hence the neutral sentiment. XOM The article mentions Exxon Mobil Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Exxon Mobil's performance or pipeline progress are provided, hence the neutral sentiment. XPER The article mentions Xperi Holding Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Xperi Holding's performance or pipeline progress are provided, hence the neutral sentiment. XPO The article mentions XPO Logistics, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about XPO Logistics' performance or pipeline progress are provided, hence the neutral sentiment. XRAY The article mentions DENTSPLY SIRONA Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about DENTSPLY SIRONA's performance or pipeline progress are provided, hence the neutral sentiment. YETI The article mentions YETI Holdings, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about YETI Holdings' performance or pipeline progress are provided, hence the neutral sentiment. YRD The article mentions Yiren Digital Energy Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Yiren Digital Energy's performance or pipeline progress are provided, hence the neutral sentiment. YUM The article mentions Yum! Brands, Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Yum! Brands' performance or pipeline progress are provided, hence the neutral sentiment. ZBRA The article mentions Zebra Technologies Corporation in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Zebra Technologies' performance or pipeline progress are provided, hence the neutral sentiment. ZLAB The article mentions Zai Lab Limited in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Zai Lab's performance or pipeline progress are provided, hence the neutral sentiment. ZYME The article mentions Zymeworks Inc. in the context of a list of companies involved in the chronic myeloid leukemia (CML) clinical trial pipeline. No specific details about Zymeworks' performance or pipeline progress are provided, hence the neutral sentiment.

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight New York, USA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia clinical trial analysis report delivers important insights into ongoing research of 25+ pipeline chronic myeloid leukemia drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Chronic Myeloid Leukemia Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for chronic myeloid leukemia across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the chronic myeloid leukemia domain.

Chronic Myeloid Leukemia Clinical Trial Analysis Summary

Request a sample and discover the recent advances in chronic myeloid leukemia treatment @ https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-pipeline-insight

What is Chronic Myeloid Leukemia?

Chronic myeloid leukemia (CML) is a type of blood cancer that develops in the bone marrow and primarily affects the myeloid cells responsible for producing blood cells. It is characterized by the abnormal growth of white blood cells and is most commonly associated with a genetic change known as the Philadelphia chromosome, which results from the fusion of the BCR and ABL1 genes. This fusion produces the BCR-ABL1 protein, an abnormal tyrosine kinase that promotes uncontrolled cell growth. CML typically progresses through three phases, chronic, accelerated, and blast phase, with most patients diagnosed during the chronic phase. The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, has significantly improved treatment outcomes and transformed CML into a largely manageable chronic condition for many patients.

Find out more about treatment for chronic myeloid leukemia @ Chronic Myeloid Leukemia New Treatment

A snapshot of the Pipeline Chronic Myeloid Leukemia Drugs mentioned in the report:

Learn more about the chronic myeloid leukemia latest research @ Chronic Myeloid Leukemia Clinical Trials

As Stuti Mahajan, consulting manager at DelveInsight, chronic myeloid leukemia is driven by the BCR::ABL1 fusion, with tyrosine kinase inhibitors (TKIs) transforming it into a largely manageable long-term disease. The market is evolving from established TKI therapies toward newer, more selective agents and treatment strategies aimed at addressing resistance, intolerance, deeper molecular responses, and treatment-free remission, supporting continued innovation despite a mature treatment landscape.

Recent Developments in Chronic Myeloid Leukemia Treatment Space

Scope of the Chronic Myeloid Leukemia Pipeline Report

Dive deep into rich insights for chronic myeloid leukemia cure, visit @ Chronic Myeloid Leukemia News

Table of Contents

For further information on the chronic myeloid leukemia clinical trials, reach out @ Chronic Myeloid Leukemia Medication

Related Reports

Chronic Myeloid Leukemia Market

Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CML companies, including Enliven Therapeutics, Ascentage Pharma, Takeda Pharmaceuticals, Terns Pharmaceuticals, and others.

Chronic Phase Myeloid Leukemia Market

Chronic Phase Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic phase myeloid leukemia companies, including Novartis, Bristol Myers Squibb, Pfizer, Takeda Pharmaceutical, Otsuka Pharmaceutical, Incyte, Ascentage Pharma, Sun Pharmaceutical, Teva Pharmaceuticals, Aurobindo Pharma, Innovent Biologics, Cipla, Dr. Reddy’s Laboratories, Lupin, Amneal Pharmaceuticals, Viatris, Accord Healthcare, Il-Yang Pharmaceutical, Bio-Path Holdings, Orca Bio, and others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Daiichi Sankyo, Agios Pharma, Astellas Pharma, Rigel Pharmaceuticals, Jazz Pharmaceuticals, Novartis, Pfizer, Abbvie, BMS, Arog Pharmaceuticals, Actinium Pharmaceutical, Astex Pharmaceutical, Syndax, Geron, SELLAS Life Sciences, Johnson & Johnson Innovative Medicine, Sanofi, Affimed, Sumitomo Pharma, Kura Oncology, CULLINAN THERAPEUTICS, Molecular Partners, Caribou Biosciences, BioPath Holdings, and others.

Acute Myeloid Leukemia Clinical Trial Analysis

Acute Myeloid Leukemia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Changzhou Qianhong Bio-pharma Co., Ltd., Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics, Lomond Therapeutics, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, and others.

Myelofibrosis Market

Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myelofibrosis companies, including PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.